The Companion Diagnostic Risk: When Your Drug Depends on a Test You Don't Control

← Back to All Insights

Precision medicine has driven a steady increase in FDA approvals that depend on a paired companion diagnostic test to identify the eligible patient population. The diagnostic and the therapeutic become commercially inseparable—and operationally vulnerable. When the diagnostic developer fails to maintain market access, the therapeutic loses its patient pipeline. Diligence that examines only the drug's clinical and regulatory profile misses half the picture.

Roughly 25% of FDA's 2024 oncology approvals required a companion diagnostic. Each one carries co-dependency risk that traditional pharmaceutical diligence does not surface.

What Makes a Companion Diagnostic Different

Companion diagnostics (CDx) are regulated as Class III in vitro diagnostics requiring PMA approval. They are co-developed with the therapeutic and labeled in the drug's FDA label. The drug's indication is restricted to patients whose biomarker status is determined by the CDx. Without the CDx, the drug cannot legally be prescribed.

The Single-CDx Vulnerability

Many therapeutics launch with a single approved CDx, often from a single laboratory or instrument manufacturer. If that diagnostic developer reduces market commitment, fails to maintain CLIA certification at sufficient laboratories, or encounters supply chain disruption, the therapeutic loses access overnight. Investors regularly underestimate this concentration risk.

LDT Substitution Risk

FDA's 2024 Final Rule on Laboratory-Developed Tests (LDTs) created a new dimension to this risk. Previously, laboratories could develop their own equivalent tests under CLIA without FDA approval. The new rule phases out that flexibility. Therapeutics that relied on widespread LDT availability for biomarker testing now face a narrowing diagnostic pipeline.

Geographic and Payer Variability

CDx reimbursement varies dramatically across payers and geographies. CMS may cover the CDx under a specific MoLDx framework, while commercial payers apply step therapy or prior authorization. A therapeutic with a Medicare-favorable CDx coverage pattern can still see commercial uptake stall when private payers require alternative testing pathways.

Red Flags in Diligence

Vantage flags companion-diagnostic dependencies where: only one CDx is approved at launch; the CDx developer has shown weakening market commitment to that indication; the diagnostic's reimbursement coverage is geographically uneven; the underlying biomarker has multiple measurement methodologies with disputed clinical equivalence; or the CDx and therapeutic have different commercial owners with potentially divergent incentives.

Mitigation Patterns That Work

The companies who navigate CDx risk effectively share patterns: parallel development of a second approved CDx (post-approval supplement), investment in clinical bridging studies to support broader test acceptance, direct relationships with reference laboratories to ensure testing capacity, and commercial-team monitoring of CDx availability as a leading indicator of script volume.

Companion diagnostic dependency is not inherently a deal-breaker—it is a structural feature of precision medicine that requires its own diligence lane. Investors and acquirers who examine the therapeutic's clinical data without examining the underlying CDx infrastructure miss a category of risk that has caused launch failures even when the drug itself was approved on strong data.